This Week in Hematology — Oct 7, 2026

This AudioScholar briefing is generated by artificial intelligence for healthcare professionals and trainees. It is not medical advice.

Welcome to This Week in Hematology. This week we're covering 10 notable papers spanning bispecific antibodies moving into older and frailer patients, the fixed-duration versus continuous therapy debate in chronic lymphocytic leukemia, and genomic tools that sharpen risk prediction. Let's dive in.

Our first theme is how far T-cell engaging bispecific antibodies are travelling, from the relapsed setting into first-line therapy and into patients who were once considered too frail to treat. In Blood, Olszewski and colleagues report a phase one-two trial of subcutaneous mosunetuzumab with polatuzumab vedotin as first-line therapy for diffuse large B-cell lymphoma in patients judged unfit or frail by a simplified geriatric assessment [1]. These were genuinely older patients, with a median age of 81, and roughly four in ten patients were classed as frail. At the end of treatment about six in ten patients had responded, and just over half of patients were in complete remission. With three years of follow-up, about half of patients were alive without progression at two years. Cytokine release syndrome affected under a third of patients and was mostly grade 1, but the authors note infection-related deaths, concentrated during the COVID-19 pandemic and among frail patients. This is a single-arm study, so it supports an anthracycline-free option for carefully selected patients rather than establishing a new standard. At the other end of the fitness spectrum, also in Blood, Crombie and colleagues added glofitamab to polatuzumab-R-CHP in 41 higher-risk patients with newly diagnosed disease [2]. The best complete response rate was 95 percent, and two-year progression-free survival was also about 95 percent. By delaying glofitamab until cycle three, the investigators saw cytokine release syndrome in only one in ten patients, all grade 1, and no neurotoxicity. The numbers are striking but come from a small phase two cohort with two years of follow-up, and the authors themselves frame them as grounds for further evaluation. Turning to myeloma, a post hoc analysis of the LINKER-MM1 study in Blood Cancer Journal, led by Mian, looked at the BCMA-directed bispecific linvoseltamab by frailty status in relapsed and refractory disease [3]. Using three different frailty instruments, response rates in frail patients sat broadly in the same range as in non-frail patients, between about sixty and seventy-five percent, and severe adverse events occurred at similar rates of roughly three quarters across groups. Frail subgroups were small and the analysis was not prespecified, but together with the lymphoma data it suggests that frailty alone may not preclude bispecific therapy.

Our second theme is chronic lymphocytic leukemia, where long-term fixed-duration data and a careful review of high-risk disease pull in slightly different directions. In Leukemia, Niemann and colleagues report 67-month follow-up of the phase three GLOW trial, comparing fixed-duration ibrutinib plus venetoclax with chlorambucil-obinutuzumab in older or comorbid patients [4]. Overall survival at about five and a half years was 79 percent with ibrutinib-venetoclax versus about 61 percent with the comparator, which works out to roughly halving the risk of death. Progression-free survival was about half of patients versus fewer than one in five, and the need for second-line therapy fell by about three quarters. Patients reaching undetectable residual disease did better, especially those with unmutated IGHV, and time free of both progression and severe adverse events was nearly two years longer. The caveat is that chlorambucil-obinutuzumab is no longer a common comparator. Meanwhile in Blood, Tam, Seymour and Blombery review TP53 loss of function in the novel agent era [5]. They argue that continuous covalent BTK inhibition, with median progression-free survival of around seven years in the frontline setting, remains the de facto standard for these patients, while fixed-duration venetoclax combinations show slower clearance of residual disease and shorter disease control in this subgroup. They also point out that retreatment data specific to TP53-altered disease have not been reported. So the GLOW results strengthen fixed duration for older patients broadly, but the review flags that the TP53-altered minority remains a setting of genuine uncertainty.

Our third theme is genomic refinement of risk, with TP53 appearing again. In Blood, Streuer and colleagues analyzed over 4,500 patients with myelodysplastic neoplasms from two independent cohorts to ask why monoallelic TP53 mutations behave so variably [6]. Using a functional phenotype score derived from saturation mutagenesis screens, they found that patients with high-scoring monoallelic variants had median leukemia-free survival of about a year, versus more than three and a half years with low-scoring variants. Combining the score with variant allele frequency was even sharper: high-function, high-burden monoallelic cases behaved like multi-hit disease, while low-function, low-burden cases behaved like wild-type. This is retrospective, but it offers a plausible way to resolve a long-standing controversy in TP53 classification, pending prospective validation. Also in Blood, Zhong and colleagues profiled 569 adults from the ECOG-ACRIN E1910 trial of blinatumomab in BCR::ABL1-negative B-cell acute lymphoblastic leukemia [7]. They mapped 23 molecular subtypes, described a new subtype driven by CEBPA or CEBPB activation through enhancer hijacking, and found that adding blinatumomab to chemotherapy was associated with better survival in several subtypes, including hyperdiploid, PAX5-altered, BCR::ABL1-like JAK-STAT and KMT2A-rearranged disease. TP53 alterations and clonal hematopoiesis mutations each marked older patients with poorer chemotherapy outcomes. The authors are explicit that small numbers in several subtypes mean these associations require confirmation.

Our final theme covers salvage therapy and transplantation. In Blood, Patel and colleagues update their phase two trial of pembrolizumab with gemcitabine, vinorelbine and liposomal doxorubicin before autologous transplant in transplant-eligible relapsed or refractory Hodgkin lymphoma [8]. Among 39 patients, many with primary refractory disease, about nine in ten patients were in complete response after just two cycles, and at nearly five years only one patient had relapsed after protocol therapy, with five-year progression-free survival of 91 percent. It remains a single-arm study, but the durability supports checkpoint-based salvage as a strong bridge to transplant. For relapsed primary central nervous system lymphoma, a disease without an established salvage standard, Grommes and colleagues report the PROSPECT phase two trial of oral tirabrutinib in the United States, also in Blood [9]. In 48 patients, two thirds of patients responded and over four in ten patients achieved complete response, with responses arriving within about a month. Median response duration was about nine months, so disease control is real but limited, and severe treatment-related events occurred in about a quarter of patients, including one fatal aspergillosis. Lastly, a Blood commentary by Chao discusses the phase three Precision-T trial of a centrally manufactured, regulatory T-cell engineered allograft, now approved by the FDA [10]. Chao describes it as the first randomized multicenter demonstration that a defined graft markedly reduces moderate to severe chronic graft-versus-host disease and non-relapse mortality without losing graft-versus-leukemia effect or increasing graft failure or infection. The commentary gives no figures, so the primary trial report is the place to judge effect size.

If you only have time for one paper this week, make it the GLOW 67-month update in Leukemia [4]. A randomized overall survival advantage with a time-limited, chemotherapy-free regimen in older and comorbid patients is the kind of evidence that settles how durable fixed-duration therapy really is, while the TP53 review keeps the high-risk exception in view.

Here is what this week's evidence adds up to in Hematology. First, bispecific antibodies are showing high response rates in first-line lymphoma, both added to pola-R-CHP and as an anthracycline-free option for frail older adults, but this rests on single-arm studies and infection risk in frail patients is unresolved. Second, fixed-duration ibrutinib-venetoclax now has randomized survival data in older patients with chronic lymphocytic leukemia, whereas for TP53-altered disease continuous BTK inhibition remains the better-supported approach and retreatment data are missing. Third, functional annotation of TP53 variants may reclassify monoallelic mutations in myelodysplastic neoplasms, and genomic subtyping may predict blinatumomab benefit in adult B-cell leukemia, though both need prospective confirmation. Fourth, checkpoint-based salvage in Hodgkin lymphoma shows unusually durable remissions, and tirabrutinib offers rapid but time-limited responses in relapsed CNS lymphoma, both from phase two data.

That's your roundup for This Week in Hematology. The full transcript and references are available on the episode page in your AudioScholar library. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week.

If this weekly briefing is useful, follow the show in your podcast app so new episodes arrive automatically. And if you have a paper you have been meaning to read, upload the PDF, or paste any link, at audioscholar dot C C. We will turn it into audio like this one, in any of thirty-one languages.

This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.